Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says results of a Phase 3 study for the drug Verzenio did not meet its primary endpoint in the treatment of advanced lung cancer. The drug, also known as abemaciclib, has already received FDA approval as a treatment for breast cancer.
Lilly says the JUNIPER study evaluating Verzenio was designed to evaluate the efficacy and safety of the drug in patients with state IV non-small lung cancer who have received chemotherapy. Levi Garraway, senior vice president of global development and medical affairs for Lilly Oncology calls the outcome of the study "unfortunate."
"We remain encouraged by the antitumor activity observed with abemaciclib in this form of lung cancer where few clinical advances have been achieved," said Garraway. "As we analyze secondary endpoints and explore specific patient subgroups in order to better evaluate the prospects for abemaciclib in NSCLC, we will continue to work with the oncology community to inform potential future treatment avenues for patients with KRAS-mutated advanced lung cancer. Moreover, we have several studies ongoing of rational combinations that include abemaciclib in non-small cell lung cancer and other malignancies. We look forward to seeing the results of these studies."
Lilly says it will submit the data from the duty at a medical meeting in 2018. You can read more about the results by clicking here.